Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (10414)	2/12/2004 1:53:30 PM
From: zeta1961	Read Replies (1) \| Respond to of 52153

Ashley, great question debate on both sides of the issue...some groups/individuals who feel the FDA takes too long, is too stringent support this practice...opponents say that this practice reduces the # of patients entering clinical trials thereby prolonging/disabling the ability to prove or disprove scientifically a drug's/prodecure's efficacy... A recent one off the top of my head is with breast cancer...several years ago, it was felt that bone marrow transplant may greatly improve remission rates...many women had the procedure done...Believe it or not the Breast Cancer Alliance folk were opposed to this ...they subsequently found out in clinical trials that bone marrow transplant does not have the remission rates hoped for...The alliance feels that we would have known this earlier had women enrolled in trials instead of using this therapy "off label"...thus also precluded women from subjecting themselves to this inherently high-risk procedure... Personally, I have mixed feelings, depending on the condition and how closely it hits home Zeta